The Expression of MicroRNA-598 Inhibits Ovarian Cancer Cell Proliferation and Metastasis by Targeting URI

Feng Xing,1,3 Shuo Wang,2,3 and Jianhong Zhou1

1Department of Obstetrics and Gynecology, Shanghai Tenth People’s Hospital of Tongji University, Tongji University School of Medicine, No. 301 Middle Yan Chang Road, Shanghai, 200072, China; 2Department of Ultrasound, Tongji Hospital, Tongji University School of Medicine, Shanghai, 200072, China

Unconventional prefoldin RPB5 interactor (URI, or RMP, a member of the prefoldin family of molecular chaperones) exhibits oncogenic activity in several types of cancer, including ovarian cancer. However, the underlying regulatory mechanism in ovarian cancer remains unclear. MicroRNAs (miRNAs) negatively regulate gene expression, and their dysregulation has been implicated in tumorigenesis. To elucidate the role of miRNAs in URI-induced ovarian cancer, miR-598 and URI were overexpressed in the SKOV3 ovarian cancer cell line. The CCK8 kit was used to determine cell proliferation, and the Transwell assay was used to measure cell invasion and migration. RT-PCR and western blotting were used to analyze the expression of miR-598 and URI. Nude mice were used to characterize the regulation of tumor growth in vivo. The results showed that the expression of miR-598 inhibited the proliferation, invasion, and migration of ovarian cancer cells by targeting URI. The inhibitory effect of miR-598 was reversed by overexpression of URI. The luciferase reporter assay showed that miR-598 downregulated URI by directly targeting the 3’ UTR of URI. In vivo studies showed that the expression of miR-598 significantly inhibited the growth of tumors. Taken together, the results suggested that miR-598 inhibited tumor growth and metastasis by targeting URI.

RESULTS
miR-598 Overexpression Significantly Inhibits Cell Proliferation, Migration, and Invasion
To investigate the role of miR-598 in SKOV3 cells, miR-598 overexpression vector (miR-598 mimic) was transfected into SKOV3 cells using Lipofectamine 2000 for 48 hr. The results showed that miR-598 was significantly upregulated by transfection with miR-598 mimic (Figure 1A). Cell proliferation was determined using Cell Counting Kit-8 (CCK-8), with 1 × 10^4 cells used as the initial concentration. After culturing for different times (0, 24, 48, and 72 hr), cell proliferation was detected by measuring the absorbance at 450 nm.

Received 16 May 2018; accepted 2 December 2018; https://doi.org/10.1016/j.omto.2018.12.002.
1Senior author

Correspondence: Feng Xing, Department of Obstetrics and Gynecology, Shanghai Tenth People’s Hospital of Tongji University, Tongji University School of Medicine, No. 301 Middle Yan Chang Road, Shanghai, 200072, China. E-mail: xingfeng063394@163.com

Correspondence: Jianhong Zhou, Department of Obstetrics and Gynecology, Shanghai Tenth People’s Hospital of Tongji University, Tongji University School of Medicine, No. 301 Middle Yan Chang Road, Shanghai, 200072, China. E-mail: 13918173861@163.com

MicroRNAs (miRNAs) are a class of evolutionarily conserved non-coding RNAs that regulate the expression of their target genes at the post-transcriptional level by binding to their 3’ UTR.10 The role of miRNAs in various biological processes, such as cellular proliferation, apoptosis, invasion, and migration, has been well established.11,12 miRNAs perform oncogenic or tumor suppressor functions in carcinogenesis based on the function of their target proteins.13,14 A recent bioinformatics analysis (https://www.genecards.org/) showed that miR-598 targets the 3’ UTR of URI. A previous study showed that miR-598 inhibits metastasis in colorectal cancer.15 However, the role of miR-598 in ovarian cancer remains unclear. In the present study, we investigated whether the miR-598-URI interaction inhibited ovarian cancer progression, and the results showed that increased miR-598 expression significantly reversed URI-induced ovarian cancer cell migration, invasion, and proliferation. In addition, we identified miR-598 as a negative regulator of URI expression in ovarian cancer cell lines.

INTRODUCTION
URI (unconventional prefoldin RPB5 interactor), or RMP (RPB5-mediating protein), is a member of the prefoldin family of molecular chaperones. URI functions as a scaffolding protein and plays critical roles in ubiquitination and transcription. This may be partially attributed to the interaction between URI and the RNA polymerase II subunit RPB5, as well as the formation of protein complexes with other protein peptides.1,2 Previous studies show that URI participates in the target of Rapamycin (TOR) signaling pathway, suggesting its potential involvement in cancer development.3 Increasing evidence suggests that URI is important for tumor progression in various cancers, including hepatocellular carcinoma,4 prostate cancer,5 colorectal cancer,6 and cervical cancer.7 This oncogenic property was further confirmed by studies showing that URI is amplified in ovarian cancer cells.8,9 However, the underlying regulatory mechanism remains unclear.
miR-598 overexpression significantly suppressed cell proliferation at 48 hr in SKOV3 cells. However, there was no significant difference after transfection with the miR-598-NC vector compared with the control group (Figure 1B). To determine the effect of miR-598 on metastasis, Transwell migration (Figure 1C) and invasion (Figure 1D) assays were performed using SKOV3 cells transfected with the miR-598 mimic, miR-598-NC, or their respective controls. The miR-598-transfected ovarian cancer cells showed significantly lower migration and invasion than those of the control or miR-598-NC group when using the Boyden Transwell assay. Taken together, these results showed that miR-598 inhibited ovarian cancer cell proliferation, migration, and invasion in vitro.

URI Overexpression Reverses the miR-598-Induced Inhibition of Cell Proliferation, Migration, and Invasion

Previous studies showed that URI acts as an oncoprotein in solid tumors. To determine whether URI was involved in miR-598-mediated tumor cell proliferation regulation, a URI overexpression vector was constructed and transfected into SKOV3 cells. Western blot analysis showed that the expression of URI was significantly upregulated in SKOV3 cells transfected with the URI overexpression vector (Figure 2A). Previous studies reported that the expression of miR-598 significantly inhibited proliferation of SKOV3 cells. URI overexpression reversed the miR-598-induced inhibition of SKOV3 cell proliferation (Figure 2B). Transwell migration and invasion assays were performed using SKOV3 cells, and the results showed that URI transfection of ovarian cancer cells significantly reversed the miR-598-induced inhibition of migration (Figure 2C) and invasion (Figure 2D), as shown in the Boyden Transwell assay. The study also found that miR-598 overexpression suppressed Bcl-2 expression, whereas it increased the levels of cleaved caspase-3. URI overexpression reversed miR-598-induced inhibition of cell proliferation. We also showed that URI overexpression enhanced cancer cell proliferation and migration with higher levels of Snail and Vimentin (Figure S1). Taken together, the results showed that the antitumor effect of miR-598 on ovarian cancer cells was decreased after overexpression of URI.
URI Is a Direct Target of miR-598

To determine the possible interaction between miR-598 and URI, a bioinformatics analysis (https://www.genecards.org/) found that there were three 3' UTR binding sites between miR-598 and URI (Figure 3A). A mutated version of the URI 3' UTR was constructed, in which nine complementary nucleotides in the binding site were altered (Figure 3B). This mutated construct was fused to the luciferase coding region (PYr-URI 3' UTR) and co-transfected into HEK293T cells along with miR-598 mimic (Figure 3B). The relative luciferase activity showed that, when the wild-type RGS-17 3' UTR was co-transfected with miR-598 mimic, URI expression was significantly decreased (p < 0.001) compared with co-transfection with the control miRNA. However, this effect was not observed in cells transfected with the mutant 3' UTR of URI, indicating that miR-598 specifically targets and inhibits the 3' UTR of URI. Western blots (Figures 3C and 3D) and RT-PCR (Figure 3E) analyses confirmed that miR-598 expression significantly inhibited URI expression at both protein and mRNA levels in vitro.

miR-598 Expression Inhibits Tumor Growth In Vivo

The aforementioned results showed that overexpression of miR-598 played an important role in inhibiting ovarian cancer cell growth in vitro. To determine whether miR-598 had a similar antitumor effect in vivo, SKOV3 cells stably expressing miR-598 or not were subcutaneously inoculated into nude mice (n = 6 for each group). The size of SKOV3 tumors in the mice was measured using a caliper every 5 days. The results showed that tumor volume and weight were significantly lower in the group treated with the miR-598 mimic than in the control groups (Figures 4A–4C). The expression of URI in xenograft tumors was determined using western blotting (Figure 4D) and RT-PCR (Figure 4E). The results showed that URI expression was downregulated in xenograft tumors from the miR-598 mimic group, compared with the xenograft tumors of the control groups. Live imaging showed that miR-598 overexpression decreased metastasis of miR-598 cells at 30 days after intravenous tail injection (Figure 4F). Taken together, the results showed that upregulation of miR-598 inhibited ovarian cancer growth and metastasis in vivo and that this inhibition may be related to the regulation of URI levels.
DISCUSSION
The present study initially examined the effect of miR-598 expression on proliferation, invasion, and migration of the SKOV3 ovarian cancer cell line. The results showed that overexpression miR-598 significantly suppressed proliferation, invasion, and migration of ovarian cancer cells, suggesting that miR-598 exerts antitumor effects. An increasing number of studies indicate that miR-598 is downregulated during tumorigenesis in various cancers, including breast cancer and colorectal cancer. Changes in the expression of miR-598 are associated with antitumor effects, suggesting that miR-598 plays an important role in regulating tumorigenesis. Thus, investigating the mechanisms underlying the involvement of miR-598 in different types of cancer may have important clinical implications.

In contrast to miR-598, the expression of URI is related to tumorigenesis. Recent studies show that URI is upregulated and promotes tumor growth and migration in various cancers, including human prostate cancer, colorectal cancer, uterine carcinosarcoma, and cervical cancer. In addition, URI expression is related to the progression of ovarian cancer. Assessment of expression levels of URI in different ovarian cancer cell lines showed that URI is upregulated, compared with the normal human ovarian surface epithelium. To assess the potential involvement of URI in the miR-598-mediated regulation of proliferation, invasion, and migration in ovarian cancer, a URI overexpression vector was constructed and transfected into SKOV3 cells. The results showed that URI overexpression reversed the miR-598-induced inhibition of proliferation, invasion, and migration in ovarian cancer cells by upregulating the migration-related epithelial-to-mesenchymal transition (EMT) markers Vimentin and Snail and downregulating the apoptosis-related protein cleaved caspase-3. The bisulfuorescin test confirmed that miR-598 interacted with the 3' UTR of URI and post-transcriptionally downregulated URI expression. The results also showed that miR-598 inhibited cell proliferation, invasion, and migration of ovarian cancer by
downregulating URI, but the previous study found that miR-598 was upregulated in colorectal cancer tissues in comparison with matched non-tumor tissues. The expression of miR-598 promotes cell proliferation and cell-cycle progression in human colorectal carcinoma by suppressing inositol polyphosphate-5-phosphatase expression.20 Another study found that miR-598 acts as a tumor suppressor in human gastric cancer by targeting IGF-1R.21 This suggests that the function of miR-598 is relative to the tumor types. However, the exact regulatory mechanism by which URI promotes cell proliferation, invasion, and migration of ovarian cancer remains unknown and needs further study.

In conclusion, the present study showed that miR-598 inhibited cell proliferation, invasion, and migration in ovarian cancer by targeting the 3′ UTR of URI. miR-598 may, therefore, be a novel diagnostic and therapeutic option for the treatment of patients with ovarian cancer.

MATERIALS AND METHODS

Ethics Statement

All animals were treated in accordance with the Guide for the Care and Use of Laboratory Animals, and all experiments were approved and performed according to the guidelines of the Ethics Committee of Shanghai Tenth People’s Hospital of Tongji University, Shanghai, China. All surgical procedures were performed under anesthesia, and every effort was made to minimize suffering. Mice were anesthetized by intraperitoneal injection of sodium pentobarbital (30 mg/kg).

Cell Lines and Culture

SKOV3 and HEK293T cells were obtained from the American Type Culture Collection (Manassas, VA, USA). SKOV3 cells were cultured in RPMI 1640 (Invitrogen, Carlsbad, CA, USA), and HEK293T cells were cultured in DMEM (Invitrogen) supplemented with 10% fetal bovine serum (FBS; Invitrogen) at 37°C in 5% CO2.

Transfection of Cells with the miR-598 Mimic Vector or URI Overexpression Vector

For miR-598 overexpression, the miR-598 mimic (5′-UACGUCA UCGUUGUAUCGUCA UU-3′) and the corresponding negative control (NC) (5′-UAUUAACGCAGGCGGCCCUUCA UU-3′) (miR-NC) were purchased from GenePharma (Shanghai, China). SKOV3 cells were transfected with either the miR-598 mimic or miR-NC at a final concentration of 50 nM using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s protocol. Cells were used for miR-598 expression analysis or other experiments after 48 hr of transfection.

For the overexpression of URI, human URI cDNA with the 3′ UTR was cloned into the pMSCV-hygro vector. The primers corresponded to the NCBI Reference Sequence Database (NCBI: AK292170.1), and involved the following: forward, 5′-CAGAGCTCATGCCCTTC GAAAAGACTCA-3′ and reverse, 5′-GTTCTAGACCCCCAGT AAAACAGTACCTTC-3′. The URI cDNA was inserted into a pMSCV-hygro Simple Vector (Takara, Otsu, Japan) to form the pMSCV-hygro-URI vector. Following sequencing, the recombinant segment of the correct clone was digested by BamHI and XbaI (Takara, Otsu, Japan). The recombinant segment was inserted into pMSCV-hygro, which was digested using the same two restriction endonucleases. The pMSCV-hygro-URI clones were sequenced, and the correct clones were amplified and identified by restriction enzyme digestion.

The day before transfection, approximately 1 × 10⁶ SKOV3 cells were seeded in media onto a 60-mm dish and incubated for 24 hr. The next
day, the cells were transfected using the Sofast Transfection Reagent kit (Sunma, Xiamen, China) according to the manufacturer’s instructions. The transfected cells were selected using G418 for 3–4 weeks for subsequent experiments. The monoclonal cells were then cloned and screened for URI expression.

RNA and miRNA Extraction and Real-Time PCR
Total RNA was isolated from SKOV3 cells using TRIzol reagent. First-strand cDNA was synthesized using the PrimeScript RT Master Mix (Perfect Real Time) Kit (RR036A, Takara), which was then used for real-time PCR, together with forward and reverse primers, and the Power SYBR Green PCR Master Mix (Life Technology, USA). GAPDH was used as an internal control. miRNA from SKOV3 cells was extracted according to the manufacturer’s instructions using a miRNA kit (Ambion, Foster City, CA, USA), and the expression levels of miRNA-598 were detected using the Power SYBR Green PCR Master Mix, with GAPDH small nuclear RNA as an internal control. The relative expression of target genes was determined using the $2^{-ΔΔCt}$ method.

Cell Viability Assay
CCK8 was used to assess cell viability. SKOV3 cells (1 × 10^5) were seeded into a 96-well plate and incubated overnight in the previously described conditions. Following this, the medium was removed, and the cells were washed three times with PBS. DMEM (90 μL) and CCK8 (10 μL) were subsequently added to each well and incubated for 1.5 hr at 37°C; a microplate reader was used to measure the optical density (OD) at 450 nm.

Boyden Chamber Assay
A migration assay was performed using a Boyden chamber (8 μm; Corning, Corning, NY, USA) containing a polycarbonate membrane. For the invasion assay, 60 μL Matrigel (BD Biosciences, Franklin Lakes, NJ, USA) was used to mimic the basement membrane. Briefly, 100 μL of 1 × 10^6 cells in serum-free medium was added to the upper chamber, and 600 μL appropriate medium with 10% FBS was added to the lower chamber. Cells were incubated for 24 hr. Migratory cells on the lower surface of the random regions were fixed and stained with crystal violet for 30 s at room temperature. Photographs of five random regions were taken, and the number of cells was counted to calculate the average number of migrated cells per plate.

 Luciferase Reporter Assay
To construct luciferase reporter vectors, the 3’ UTR of URI cDNA fragments containing the predicted potential miR-598 binding sites was amplified by PCR and subcloned downstream of the luciferase gene in the psiCHECK 2 vector (Ambion). The 3’ UTR of URI with or without the mutant 3’ UTR of URI (containing the binding sites for miR-598) was amplified.

For luciferase assays, HEK293T cells were cultured in 24-well plates and co-transfected with 50 ng of the corresponding vectors containing firefly luciferase together with 25 ng miR-598 or the control. Transfection was performed using Lipofectamine 2000 reagent (Invitrogen). At 48 hr post-transfection, the relative luciferase activity was calculated by normalizing the firefly luminescence to the Renilla luminescence using the Dual-Luciferase Reporter Assay (Promega, Madison, WI, USA) according to the manufacturer’s instructions.

In Vivo Studies
Animal studies were performed according to institutional guidelines. SKOV3 cells were stably transfected with NC or miR-598 overexpression vectors. A total of 5 × 10^6 viable cells was injected into the right flanks of nude mice. Tumor sizes were measured using a vernier caliper every 5 days, and the tumor volume was calculated using the following formula: volume = 1/2 × length × width. At 30 days after implantation, the mice were sacrificed, the tumors were dissected, and tumor weights were measured.

For metastasis analysis, NC and URI-overexpressing SKOV3 cells transfected with luciferase expression vectors were injected into tails intravenously (2 × 10^5). After 30 days, metastasis of SKOV3 cells was analyzed by bioluminescence imaging with intravenous injection of luciferin (150 mg luciferin per kilogram of body weight).

Western Blot Analysis
Protein was extracted from tissues and cells using RIPA lysis buffer containing proteinase inhibitor (Sigma-Aldrich, Otsu, Japan). The protein concentration was determined using the BCA Protein Assay Kit (Vigorous Biotechnology Beijing, Beijing, China). Equal amounts of protein lysates (20 μg each lane) were resolved using 10% SDS-PAGE gels and then electroblotted onto nitrocellulose membranes (Millipore, Madison, WI, USA). The membranes were blocked for 2 hr with 5% non-fat dry milk in Tris-buffered saline containing 0.1% Tween 20, and incubated at 4°C overnight with the following primary antibodies: mouse monoclonal anti-human IRS-1 (1:1,000, Santa Cruz Biotechnology, Santa Cruz, CA, USA), mouse monoclonal anti-human URI (1:500, Santa Cruz Biotechnology), and mouse monoclonal anti-human GAPDH (1:5,000, Santa Cruz Biotechnology). GAPDH was used as an internal control for protein loading. The membrane was further incubated with horseradish-peroxidase-conjugated goat anti-mouse immunoglobulin G (lgG) (1:5,000, Santa Cruz Biotechnology) for 1 hr at room temperature. The immune complexes were detected by enhanced chemiluminescence (ECL; Cell Signaling Technology, Danvers, MA, USA). The integrated density of the band was quantified by Quantity One software (Bio-Rad, Hercules, CA, USA).

Statistical Analysis
Continuous variables were expressed as the mean ± SD. One-way ANOVA was performed for multiple comparisons using GraphPad Prism software, v5.0 (GraphPad, La Jolla, CA, USA). p values ≤ 0.05 indicated a statistically significant difference.

SUPPLEMENTAL INFORMATION
Supplemental Information includes one figure and can be found with this article online at https://doi.org/10.1016/j.omto.2018.12.002.
REFERENCES

1. Dorjsuren, D., Lin, Y., Wei, W., Yamashita, T., Nomura, T., Hayashi, N., and Murakami, S. (1998). RMP, a novel RNA polymerase II subunit 5-interacting protein, counteracts transactivation by hepatitis B virus X protein. Mol. Cell. Biol. 18, 7546–7555.

2. Gstaiger, M., Luke, B., Hess, D., Oakeley, E.J., Wirbelauer, C., Blondel, M., Vigneron, M., Peter, M., and Krek, W. (2003). Control of nutrient-sensitive transcription programs by the unconventional prefoldin URI. Science 302, 1208–1212.

3. Delgermaa, L., Hayashi, N., Dorjsuren, D., Nomura, T., Thuy, T.T., and Murakami, S. (2004). Subcellular localization of RPB5-mediating protein and its putative functional partner. Mol. Cell. Biol. 24, 8556–8566.

4. Yang, H., Gu, J., Zheng, Q., Li, M., Lian, X., Miao, J., Jiang, J., and Wei, W. (2011). RPB5-mediating protein is required for the proliferation of hepatocellular carcinoma cells. J. Biol. Chem. 286, 11865–11874.

5. Mita, P., Savas, J.N., Briggs, E.M., Ha, S., Gnanakkan, V., Yates, J.R., 3rd, Robins, D.M., David, G., Boeke, J.D., Garabedian, M.J., and Logan, S.K. (2016). URI regulates KAP1 phosphorylation and transcriptional repression via PP2A phosphatase in prostate cancer cells. J. Biol. Chem. 291, 25516–25528.

6. Lipinski, K.A., Britschgi, C., Schrader, K., Christinat, Y., Frischknecht, L., and Krek, W. (2016). Colorectal cancer cells display chaperone dependency for the unconventional prefoldin URI. Oncotarget 7, 29635–29647.

7. Gu, J., Li, X., Liang, Y., Qiao, L., Ran, D., Lu, Y., Li, X., Wei, W., and Zheng, Q. (2013). Upregulation of URI/RMP gene expression in cervical cancer by high-throughput tissue microarray analysis. Int. J. Clin. Exp. Pathol. 6, 669–677.

8. Noske, A., Henrixen, L.A., Laffleur, B., Zimmermann, A.K., Tubbs, A., Singh, S., Storzer, M., Fink, D., and Moeh, H. (2015). Characterization of the 19q12 amplification including CCNE1 and URI in different epithelial ovarian cancer subtypes. Exp. Mol. Pathol. 98, 47–54.

9. Theurillat, J.P., Metzler, S.C., Henzi, N., Diouder, N., Helbling, M., Zimmermann, A.K., Jacob, F., Soltermann, A., Caduff, R., Heinzelmann-Schwarz, V., et al. (2011). URI is an oncogene amplified in ovarian cancer cells and is required for their survival. Cancer Cell 19, 317–332.

10. Lim, L.P., Lau, N.C., Garrett-Engele, P., Grimson, A., Schelter, J.M., Castle, J., Bartel, D.P., Linsley, P.S., and Johnson, J.M. (2005). Microarray analysis shows that some microRNAs downregulated at large numbers of target mRNAs. Nature 433, 769–773.

11. Bartel, D.P. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281–297.

12. Makeyev, E.V., and Maniatis, T. (2008). Multilevel regulation of gene expression by microRNAs. Science 319, 1789–1790.

13. Iorio, M.V., and Croce, C.M. (2009). MicroRNAs in cancer: small molecules with a huge impact. J. Clin. Oncol. 27, 5848–5856.

14. Garofalo, M., and Croce, C.M. (2011). microRNAs: master regulators as potential therapeutics in cancer. Annu. Rev. Pharmacol. Toxicol. 51, 25–43.

15. Chen, J., Zhang, H., Chen, Y., Qiao, G., Jiang, W., Ni, P., Liu, X., and Ma, L. (2017). miR-598 inhibits metastasis in colorectal cancer by suppressing JAG1/Notch2 pathway stimulating EMT. Exp. Cell Res. 352, 104–112.

16. Fan, J.L., Zhang, J., Dong, L.W., Fu, W.J., Du, J., Shi, H.G., Jiang, H., Ye, F., Xi, H., Zhang, C.Y., et al. (2014). URI regulates tumorigenicity and chemotherapeutic resistance of multiple myeloma by modulating IL-6 transcription. Cell Death Dis. 5, e1126.

17. Wang, Y., Garabedian, M.J., and Logan, S.K. (2015). URI amplification in uterine carcinosarcoma associates with chemo-resistance and poor prognosis. Am. J. Cancer Res. 5, 2320–2329.

18. Fu, L., Li, Z., Zhu, J., Wang, P., Fan, G., Dui, Y., Zheng, Z., and Liu, Y. (2016). Serum expression levels of microRNA-382-3p, -598-3p, -1246 and -184 in breast cancer patients. Oncol. Lett. 12, 269–274.

19. Gu, J., Liang, Y., Qiao, L., Lu, Y., Hu, D., Li, N., Zhang, L., Chen, Y., Du, J., and Zheng, Q. (2015). URI expression in cervical cancer cells is associated with higher invasion capacity and resistance to cisplatin. Am. J. Cancer Res. 5, 1353–1367.

20. Li, K.P., Fang, Y.P., Liao, J.Q., Duan, J.D., Feng, L.G., Luo, X.Z., and Liang, Z.J. (2018). miR-598 promotes cell proliferation and cell cycle progression in human colorectal carcinoma by suppressing INPP5E expression. Mol. Med. Rep. 17, 2991–2997.

21. Liu, N., Yang, H., and Wang, H. (2018). miR-598 acts as a tumor suppressor in human gastric cancer by targeting IGF-1R. Oncotargets Ther. 11, 2911–2923.